Summit Therapeutics

Canaccord Genuity is pleased to announce that on September 13, 2017, it completed a public offering of American Depositary Shares for Summit Therapeutics. (NASDAQ: SMMT). The Company issued a total of 1,459,000 American Depositary Shares (“ADSs”) at a public offering price of $12.00 per ADS, before underwriting discounts and commissions. Each ADS represents five ordinary shares of Summit. Following the offering, the ADSs will trade on the NASDAQ Global Market. Canaccord Genuity acted as Lead Joint Bookrunning Manager for the offering.

Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection.